Genetic Technologies Limited
Registered Office
60-66 Hanover Street
Fitzroy
Victoria
3065
Tel: 61-3-9415-1135
Fax: 61-3-9417-2987
Website: http://www.gtg.com.au/
Email: info@gtg.com.au
191 articles about Genetic Technologies Limited
-
US Patent Office Grants Key Risk Test Patent
6/18/2020
Molecular diagnostics company Genetic Technologies Limited is pleased to announce the issuance of US Patent No: US 10,683,549, Methods for assessing risk of developing breast cancer.
-
Genetic Technologies Announces Closing of $8.0 Million Public Offering
5/28/2020
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced public offering of 3,500,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at an effective purchase price of $2.00 per ADS,
-
Genetic Technologies Announces Pricing of $8.0 Million Public Offering
5/26/2020
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has priced a public offering of 4,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents), each representing six hundred (600) of the Company’s ordinary shares, at an effective purchase price of $2.00 per ADS (or ADS equivalent). The closing of the offering is expected to
-
Genetic Technologies Provides Operational Update - Successful Prototype Polygenic Risk Score for COVID-19 Created
5/22/2020
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) provides the following operational updates: Normal commercial operations will recommence from 1 June 2020 Confirmed that a prototype polygenic risk score can successfully discriminate between COVID-19 patients who required hospitalization from those who did not require hospitalization Continued discussions with third parties around use of existing CLIA and NATA accr
-
Genetic Technologies - Accelerated development of new COVID-19 Polygenic Risk Test for Risk of Developing Life-Threatening Complications
5/20/2020
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is to commence accelerating development of a polygenic risk score (PRS) test to predict an individual’s risk of developing life-threatening complications should they become infected with COVID-19. Dr George Muchnicki CEO said " GENE has secured a data set of over 1,500 patients who experienced COVID-19 and we intend on leveraging our core expertise in predictive risk modelling, to a
-
Genetic Technologies Announces Closing of $1.44 Million Registered Direct Offering
4/23/2020
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct offering of 722,502 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $2.00 per ADS for gross proceeds of approximately $1.44 million. H.C. Wainwright &
-
Genetic Technologies Announces $1.44 Million Registered Direct Offering
4/20/2020
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 722,502 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $2.00 per
-
COVID-19 Testing Capacity at Genetic Technologies Accredited LaboratoryTemporary transition to high throughput COVID-19 testing
4/17/2020
Genetic Technologies Limited has developed a detailed implementation plan to enable a temporary transition of our genetic testing laboratory to a high-throughput COVID-19 testing laboratory, should it be required by Government agencies to assist with demand.
-
Genetic Technologies Announces Closing of $1.8 Million Registered Direct Offering
4/6/2020
Genetic Technologies Limited announced the closing of the previously announced registered direct offering of 1,028,574 American Depositary Shares, each representing six hundred of the Company’s ordinary shares, at a purchase price of $1.75 per ADS.
-
Genetic Technologies Limited Announces Market Update on Sales, Early Test Results and Launch of Consumer Initiated Testing
4/1/2020
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market. Breast Cancer and Colorectal Cancer tests commissioned, and sales commenced First Quarter 2020 with over 100 test kits distributed. Early data generated from tests identified a number of high-risk individuals leading to personalised care plans designed for early detection Consumer Initiated Tes
-
Genetic Technologies Announces $1.8 Million Registered Direct Offering
4/1/2020
Genetic Technologies Limited announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 1,028,574 American Depositary Shares, each representing six hundred of the Company’s ordinary shares, at a purchase price of $1.75 per ADS.
-
Genetic Technologies Limited Announces Receipt of Delisting Notification Letter from Nasdaq
3/14/2020
Genetic Technologies Limited announced that after the close of the ASX market on March 13, 2020, it received a determination letter from The Nasdaq Stock Market LLC indicating that it did not comply with the Listing Rule 5550 for continued listing on the Nasdaq Capital Market
-
Genetic Technologies to provide Corporate & Strategic Update at 2020 Biotech Showcase
1/13/2020
Genetic Technologies, a leader in the development of genetic risk assessment tests, recently announced the commercial availability and US launch of the company’s GeneType for Breast Cancer in 20 centers across eight States.
-
Genetype for Breast Cancer commissioned with sales to commence First Quarter 2020
12/10/2019
Genetic Technologies Limited is pleased to announce the full commissioning of its Australian Laboratory for the provisioning of its generation 3 breast cancer test with sales to commence in Q1, 2020.
-
Genetic Technologies Interview to Air on Bloomberg International on the RedChip Money Report
11/15/2019
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company, announced today an interview with interim-CEO Dr. Jerzy Muchnicki will air on The RedChip Money Report television program.
-
Genetic Technologies Provides Shareholder Update on Recent Achievements and Upcoming Milestones
11/5/2019
Genetic Technologies Limited, a diversified molecular diagnostics company, announced an update to shareholders on recent achievements and upcoming milestones.
-
Shivom Partnership With Genetic Technologies Will Enable Better Cancer Prediction and Prevention Through Mass Genomic Data Analysis
3/6/2018
Blockchain Genomics Pioneer Joins Forces with Nasdaq-Listed Molecular Diagnostics Company To Accelerate Cancer Detection Through 'Critical Mass' of Genomics Data
-
Genetic Technologies Announces Strategic Alliance and Capital Raising
2/15/2018
In addition, in order to secure additional working capital, the Company has also mandated Lodge Corporate Pty Ltd to assist in a proposed private placement of up to 324.7 million new GTG fully paid ordinary shares at an issue price of 0.014c per GTG share.
-
Genetic Technologies Limited: Update on Strategic Alliance
2/12/2018
GTG will provide a market update as soon as it is able to conclude that review by the ASX.
-
Mr Buccilli commenced with the Company in June 2014 as CFO and was appointed CEO in February 2015.